Telix Pharmaceuticals Limited (TLX.AX)

18,65 +0,25 (+1,36%) Al cierre: 04:10PM AEST

Telix Pharmaceuticals Limited

55 Flemington Road
Suite 401
North Melbourne, VIC 3051
Australia
61 3 9093 3855
https://telixpharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 415

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA,	Co-Founder, MD, Group CEO & Executive Director	669,24k	N/A	1976
Mr. Darren Smith B.Bus., FCPA, M.B.A.	Group Chief Financial Officer	571,17k	N/A	1965
Dr. Andreas Kluge M.D., Ph.D.	Chief Medical Advisor & Non-Executive Director	43k	N/A	1965
Dr. David N. Cade M.B.A., M.D., MBBS	Group Chief Medical Officer	N/A	N/A	1969
Mr. Richard Valeix M.B.A.	Group Chief Commercial Officer	638,49k	N/A	1975
Mr. Darren Patti	Group Chief Operating Officer	N/A	N/A	1972
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D.(Cantab)	Chief Scientist	141,76k	N/A	N/A
Mr. Craig Ulrick	Chief Information Officer	N/A	N/A	N/A
Ms. Kyahn Williamson B.A.	Senior Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C.	Senior VP of Global Governance, Risk & Compliance	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en AUD.

Descripción

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Gobierno corporativo

El ISS Governance QualityScore de Telix Pharmaceuticals Limited, a día 1 de junio de 2024, es 5. Las puntuaciones base son Auditoría: 3; Tablero: 6; Derechos de los accionistas: 7; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.